A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys.
One thing that can help with the treatment of any disease is early detection, and Alzheimer's is no exception to that. And the good news is that in the near future, detecting cases of Alzheimer's disease could simply involve a blood test.
A new wave of blood tests involves checking for p-tau217, which is an abnormal protein that can help accurately detect 90% of Alzheimer's cases. The current detection rates are far lower than that, with one study finding that primary care doctors only detected 61% of cases correctly. While the Food and Drug Administration (FDA) has not approved any of these new tests yet, these are encouraging developments nonetheless. They could be game changers for two healthcare stocks that have approved treatments for Alzheimer's: Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB).
Eli Lilly is the largest healthcare stock in the world, with a market cap of more than $800 billion. Investors have been bullish on the business for its popular weight loss and diabetes drugs -- Zepbound and Mounjaro. But the company also has a promising early Alzheimer's treatment, which the FDA recently approved: Kisunla.
Source Fool.com
Biogen Inc. Aktie
Die Community bevorzugt Biogen Inc., mit deutlich mehr Buy- (52) als Sell-Einschätzungen (2).
Das durchschnittliche Community-Kursziel von 282 € für Biogen Inc. impliziert eine Steigerung von über 50% gegenüber 176.6 €.
